Recombinant EGFR (Cetuximab Biosimilar) 抗体
适用: 人
FACS, in vivo
宿主: 小鼠
Monoclonal
C225
unconjugated
Recombinant Antibody
-
- 抗原 See all EGFR (Cetuximab Biosimilar) products
- EGFR (Cetuximab Biosimilar)
- 抗体类型
- Recombinant Antibody
-
适用
- 人
-
宿主
- 小鼠
-
克隆类型
- 单克隆
-
标记
- This EGFR (Cetuximab Biosimilar) antibody is un-conjugated
-
应用范围
- Flow Cytometry (FACS), In vivo Studies (in vivo)
- 原理
- Cetuximab Biosimilar, Human EGFR Monoclonal Antibody
- 特异性
- The monoclonal antibody cetuximab biosimilar specifically binds to the human EGFR.
- 产品特性
- Recombinant Chimeric IgG1 Monoclonal Antibody.
- 纯化方法
- Protein A affinity column
- 纯度
- > 95% by SDS-PAGE under reducing conditions and HPLC.
- 过滤
- 0.2 μm filtered
- 内毒素水平
- < 1 EU per 1 mg of the protein by the LAL method.
- 免疫原
- The monoclonal antibody cetuximab biosimilar was produced in the cetuximab biosimilar CHO stable cell line.
- 克隆位点
- C225
- 亚型
- IgG1 kappa
-
anti-EGFR (Cetuximab Biosimilar) antibody
适用: 人 FACS, BR 宿主: Human Monoclonal C225 unconjugated Recombinant Antibody
-
- 应用备注
- ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by cetuximab.
- 限制
- 仅限研究用
-
- 状态
- Liquid
- 浓度
- 1 mg/mL
- 缓冲液
- PBS, pH 7.4, no stabilizers or preservatives.
- 储存液
- Without preservative
- 注意事项
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 储存条件
- -20 °C
- 储存方法
- 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
- 有效期
- 12 months
-
- 抗原
- EGFR (Cetuximab Biosimilar)
- Abstract
- EGFR (Cetuximab Biosimilar) 产品
- 别名
- ERBB antibody, ERBB1 antibody, HER1 antibody, PIG61 antibody, mENA antibody, epidermal growth factor receptor antibody, EGFR antibody
- 物质类
- Biosimilar
- 背景
-
Cetuximab, a chimeric (mouse/human) anti-EGFR monoclonal antibody, is an EGFR inhibitor used for the treatment of metastatic colorectal cancer and head and neck cancer. Cetuximab binds to EGFR and turns off the uncontrolled growth in cancers with EGFR mutations.
Cetuximab can be used for treatment of KRAS wild type colon cancer but has little or no effect in colorectal tumors harboring a KRAS mutation. Before treatment using Erbitux, it is better to do a diagnosis using the real time PCR companion diagnostic test for KRAS, the therascreen KRAS test.
There are four closely related receptor tyrosine kinases in the ErbB family of receptors: EGFR (ErbB-1; HER1 in humans), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Bound by members of the epidermal growth factor family (EGF-family) of extracellular protein ligands, EGFR (epidermal growth factor receptor) located on cell surface sends a signal down the MAPK pathway that includes another protein, KRAS (also spelled K-ras). Mutations affecting EGFR and/or KRAS expression or activity could result in cancer. The mutated KRAS continuously sends a growth signal to the downstream pathway, leading to uncontrollable cell division, even if EGFR has been blocked.
-
You are here:
